RD-109

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:chemical_compound
gptkbp:bfsLayer 6
gptkbp:bfsParent gptkb:RD-108_engines
gptkbp:activities inhibits tumor growth
gptkbp:affiliated_with gptkb:healthcare_organization
gptkbp:analyzes investigational drug
gptkbp:approves not yet approved
gptkbp:author gptkb:Dr._Ivan_Petrov
gptkbp:class gptkb:drug
gptkbp:clinical_trial gptkb:Russia
Phase II
Phase I
promising
gptkbp:collaborations gptkb:international_collaboration
gptkbp:composed_of gptkb:chemical_compound
gptkbp:developed_by Russian scientists
gptkbp:discovered_by 1960s
gptkbp:dissolved soluble in water
soluble in ethanol
gptkbp:ecological_role antitumor
gptkbp:environmental_impact low toxicity
gptkbp:financial_performance stable under normal conditions
gptkbp:future_plans ongoing studies
https://www.w3.org/2000/01/rdf-schema#label RD-109
gptkbp:ingredients C12 H14 N2 O3 S
gptkbp:interacts_with none reported
gptkbp:invention patented
Pharmaceutical Company X
gptkbp:investment oncology drugs
high potential
gptkbp:is_tested_for conducted
gptkbp:manager intravenous
gptkbp:market not available
gptkbp:pharmacokinetics under study
inhibits cell proliferation
gptkbp:produced_by experimental
gptkbp:products IND-123456
RD-114
gptkbp:project clinical trials
gptkbp:publishes gptkb:Journal_of_Cancer_Research
gptkbp:receives_funding_from government grants
gptkbp:regulatory_compliance pending
gptkbp:research positive results
gptkbp:research_areas gptkb:Moscow_Institute_of_Physics_and_Technology
gptkbp:research_focus oncology
gptkbp:safety_features under evaluation
gptkbp:side_effect fatigue
nausea
hair loss
gptkbp:social_structure contains a sulfonamide group
gptkbp:targets gptkb:healthcare_organization
cancer cells
gptkbp:type_of 123456-78-9
gptkbp:used_in gptkb:healthcare_organization
gptkbp:weight 270.32 g/mol